Top Markets
Coin of the day
Biocure Technology Inc. Biocure Technology Inc.

Biocure Technology Inc.

CURE
Rang in Aktien #39915
Biocure Technology Inc., operating with its subsidiary, focuses on the creation... Biocure Technology Inc., operating with its subsidiary, focuses on the creation and market introduction of biopharmaceutical innovations, particularly those involving recombinant technologies and ranibizumab. The company's current development pipeline includes: Interferons-ß, aimed at treating multiple sclerosis. Ranibizumab, a monoclonal antibody fragment designed to address macular degeneration and a related eye condition known as macular edema. Filgrastim, which targets neutropenia – a deficiency of white blood cells that can arise from cancer, bone marrow transplants, chemotherapy, or other medical issues. Additionally, Biocure is conducting research and development into several promising areas: CAR T-cell therapy, which works by identifying and eradicating cancer cells. A vaccine against foot and mouth disease. Various products for promoting hair growth. The firm was established in 2005 and its corporate headquarters are located in Vancouver, Canada.
Aktienkurs
$0.00366968
Zuletzt synchronisiert: 2024-07-12
Marktkapitalisierung
$299.46K
Veränderung (1 Tag)
-66.77%
Veränderung (1 Jahr)
0.00%
Land
CA
Handel Biocure Technology Inc. (CURE)

Kategorie

EPS für Biocure Technology Inc. (CURE)
EPS zum 2026 TTM: 0
Laut den aktuellen Finanzberichten und dem Aktienkurs von Biocure Technology Inc. beträgt das aktuelle EPS des Unternehmens (TTM) 0. Am Ende des Jahres 2026 betrug das EPS 0 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von Biocure Technology Inc. von 2026 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
Nicht genügend Daten für die angegebenen Daten.
EPS für ähnliche Unternehmen oder Wettbewerber
Unternehmen EPS EPS-Differenz Land
$17.32 -
US
$27.74 -
NL
- -
CH
- -
KR
$13.70 -
BE